BC Extra | Dec 6, 2019
Company News

FDA hold muddies Ipsen’s timeline for palovarotene in rare bone disease

A partial clinical hold on four studies of palovarotene that shaved $1.1 billion from Ipsen’s market cap on Friday could slow the biopharma’s timeline for a planned NDA to treat rare bone disease fibrodysplasia ossificans...
BC Week In Review | Nov 2, 2018
Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Oct. 29,...
BC Week In Review | Oct 26, 2018
Clinical News

Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Oct. 24 after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP)....
BC Innovations | Oct 25, 2018
Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...
BC Extra | Oct 24, 2018
Company News

Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Wednesday after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP). Clementia...
BioCentury | Aug 18, 2018
Product Development

Doing more with less

In rare diseases where natural history data are scarce, Phase II studies may have to perform dual duty to both seek efficacy signals and test out new endpoints. Ovid Therapeutics Inc. and Clementia Pharmaceuticals Inc....
BC Week In Review | May 25, 2018
Clinical News

Clementia reports Phase II data for rare bone disease candidate

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) reported data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized by heterotopic ossification (HO), or bone formation outside...
BC Extra | May 23, 2018
Clinical News

Clementia falls on Phase II data for rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) lost $4.05 (21%) to $14.85 on Wednesday after reporting data from a Phase II trial of palovarotene to treat fibrodysplasia ossificans progressiva (FOP). FOP is a rare, genetic bone disease characterized...
BC Week In Review | Dec 15, 2017
Clinical News

Clementia starts Phase III of palovarotene to treat FOP

Clementia Pharmaceuticals Inc. (Montreal, Quebec) began the Phase III MOVE trial to evaluate oral palovarotene (R667) in 80 patients with fibrodysplasia ossificans progressiva (FOP). The company plans to complete enrollment by the end of next...
BC Extra | Aug 2, 2017
Financial News

Clementia rises after pricing $120M IPO

Bone disease company Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) gained $1.35 to $16.35 in its first day of trading Wednesday after raising $120 million through the sale of 8 million shares at $15 in an IPO underwritten...
Items per page:
1 - 10 of 22